Rebif Specialty 1 carton (12 syringes) of Rebif 44mcg
Rebif Specialty helps to decrease the number of multiple sclerosis attacks and to slow physical disability in people with relapsing forms of the disease. The medicine does not cure multiple sclerosis.
The pharmacokinetics of Rebif (interferon beta-1a) in people with multiple sclerosis have not been evaluated. In healthy volunteer subjects, a single subcutaneous (sc) injection of 60 mcg of Rebif (liquid formulation), resulted in a peak serum concentration (Cmax) of 5.1 ± 1.7 IU/mL (mean ± SD), with a median time of peak serum concentration (Tmax) of 16 hours. The serum elimination half-life (t1/2) was 69 ± 37 hours, and the area under the serum concentration versus time curve (AUC) from zero to 96 hours was 294 ± 81 IU·h/mL. Following every other day sc injections in healthy volunteer subjects, an increase in AUC of approximately 240% was observed, suggesting that accumulation of interferon beta-1a occurs after repeat administration. Total clearance is approximately 33-55 L/hours. There have been no observed gender-related
effects on pharmacokinetic parameters. Pharmacokinetics of Rebif in pediatric and geriatric patients or patients with renal or hepatic insufficiency have not been established.
INDICATIONS AND USAGE
RebifÒ (interferon-beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability. Efficacy of Rebif in chronic progressive multiple sclerosis has not been established.
Rebif (interferon beta-1a) should be used with caution in patients with depression, a condition that is common in people with multiple sclerosis. Depression, suicidal ideation, and suicide attempts have been reported to occur with increased frequency in patients receiving interferon compounds, including Rebif. Patients should be advised to report immediately any symptoms of depression and/or suicidal ideation to the prescribing physician. If a patient developsdepression, cessation of treatment with Rebif should be considered.